• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Advanced Research

  2026-05-15

  Digoxin is more than a classic cardiac glycoside: its high-purity, robust Na+/K+ ATPase pump inhibition unlocks new experimental horizons in both cardiovascular and antiviral research. This guide delivers actionable protocols and troubleshooting strategies for harnessing Digoxin’s dual-domain efficacy, with a special focus on cell-specific workflows and data reproducibility.

• DeferoxamineB in Cancer Research: Protocols & Innovations

  2026-05-15

  Explore how Deferoxamine (DeferoxamineB) enables precise control of iron metabolism and regulated cell death in advanced cancer models. This article delivers actionable experimental workflows, protocol optimizations, and troubleshooting strategies rooted in the latest metabolic intervention research, setting a new standard for oncology assay design.

• Ruxolitinib (INCB018424): Translational Leverage for JAK-STA

  2026-05-14

  This thought-leadership article explores the mechanistic and strategic implications of using Ruxolitinib (INCB018424) in translational research targeting JAK-STAT pathway inhibition. By weaving together the latest evidence, protocol parameters, and competitive considerations, we provide actionable insights for researchers in myeloproliferative disorder and oncogenic JAK2 fusion protein studies. The discussion goes beyond product basics, integrating high-dimensional immune profiling, workflow optimization, and relevance to broader immunomodulatory therapies.

• Applied Protocols for the Alcian Blue & Nuclear Fast Red Sta

  2026-05-14

  Unlock robust mucopolysaccharide and nuclear staining with the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5, enabling streamlined workflows for chondrogenic differentiation and mucin detection. This guide translates recent research and real-world lab scenarios into actionable protocols, troubleshooting, and optimization tips.

• PPM-18: Precision iNOS Inhibition for Sepsis Research Workfl

  2026-05-13

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) empowers researchers with robust, selective inhibition of the NF-κB/iNOS axis for inflammation and sepsis models. Its solubility, reproducibility, and protocol-ready profile make it a standout tool for dissecting immune response mechanisms and optimizing anti-inflammatory assays.

• Docetaxel as a Microtubule Stabilizer in Cancer Chemotherapy

  2026-05-13

  Harness the unique microtubule-stabilizing power of Docetaxel (Taxotere) to dissect mitotic arrest, apoptosis, and chemoresistance in translational cancer models. This guide delivers actionable protocols, advanced troubleshooting, and insights from both recent studies and APExBIO product expertise to power your next breast, ovarian, or gastric cancer experiment.

• Ceapin-A7 in Translational ER Stress Research: Mechanistic P

  2026-05-12

  This article explores how the selective ER stress blocker Ceapin-A7 advances mechanistic understanding and strategic design in translational research. It integrates ATF6α pathway inhibition with recent disease-model insights, critically appraises competitive research tools, and offers actionable guidance for maximizing experimental clarity and clinical relevance.

• hiPSC-Derived Intestinal Organoids for Human Pharmacokinetic

  2026-05-12

  This study establishes a robust protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, providing a superior in vitro platform for pharmacokinetic research. The model overcomes limitations of animal and Caco-2 cell systems by enabling long-term culture, differentiation, and relevant drug metabolism assessment.

• Macrophage EV-miR-660 Drives Breast Cancer Metastasis via NF

  2026-05-11

  This study uncovers how tumor-associated macrophage (TAM)-derived extracellular vesicles (EVs) containing microRNA-660 facilitate breast cancer progression. By targeting the KLHL21/IKKβ/NF-κB p65 axis, EV-miR-660 promotes cancer cell invasion and metastasis, providing mechanistic insight into tumor microenvironment-driven malignancy and highlighting potential intervention points.

• Population PK Insights: Adefovir as OAT1 Probe in Drug-Drug

  2026-05-11

  This study refines the application of Adefovir (GS-0393) as a probe for renal OAT1 transporter activity within clinical drug-drug interaction (DDI) phenotyping cocktails. Using population pharmacokinetic modeling, the authors demonstrate that systemic exposure changes under co-administration are primarily due to altered absorption or prodrug conversion, not renal elimination, providing new clarity for transporter-based DDI assessment.

• Nigericin Sodium Salt: Technical Guidance for Ion Transport

  2026-05-10

  Nigericin sodium salt is a potassium ionophore used to modulate ion gradients and cytoplasmic pH in membrane biology, toxicology, and platelet aggregation workflows. This article focuses on technical integration, solubilization, and assay optimization for research settings. It is not intended for clinical or diagnostic applications.

• Cathepsin B Inhibitor CA-074: Technical Guidance for Lab Use

  2026-05-09

  Cathepsin B inhibitor CA-074 enables selective, nanomolar-range inhibition of cathepsin B, supporting research in cancer metastasis, neurotoxicity, and immune modulation. It is best suited for studies requiring high target specificity and short-term solution stability, but should not be used for broad-spectrum cysteine protease inhibition or in workflows needing prolonged inhibitor storage.

• Cy5 Hydrazide: Precision Carbonyl Labeling for Nanoparticle

  2026-05-09

  Cy5 hydrazide (non-sulfonated) empowers researchers with robust, quantitative carbonyl labeling across protein, glycoprotein, and nanoparticle workflows. Its unique compatibility with food-grade nanotechnology and advanced oxidative stress assays sets a new standard for sensitivity and regulatory compliance.

• PP 1: Potent Src Family Tyrosine Kinase Inhibitor for Resear

  2026-05-08

  PP 1 is a selective Src family tyrosine kinase inhibitor that demonstrates nanomolar potency against Lck and Fyn, supporting advanced cancer signaling and immunology research. Its validated selectivity and strong in vitro/in vivo performance make it a preferred tool for dissecting oncogenic pathways and T cell activation modulation.

• THZ1 as a Covalent CDK7 Inhibitor: Deep Mechanistic Insight

  2026-05-07

  Explore the unique mechanism and translational impact of THZ1, a covalent CDK7 inhibitor, in transcription regulation and T-ALL research. Gain actionable insights on resistance, assay design, and protocol optimization rarely covered elsewhere.

450 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page